More on TCRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $0.92 |
|
|||
| Open | $0.92 | ||||
| 52 Wk High | $26.80 | ||||
| 52 Wk Low | $23.00 | ||||
| Day High | $0.92 | ||||
| Day Low | $0.92 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 193,597 | ||||
- Form 8-K TScan Therapeutics, Inc. For: Jun 22
- TScan reports early Phase 1 data showing chimerism gains with TSC-101
- TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Trans
- Cellares and TScan partner to evaluate automated manufacturing for cancer therapy
- Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
- Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: 667, L.P.
- Form 8-K TScan Therapeutics, Inc. For: May 20
- Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: Nicholson Garry A
- Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: Woods Keith
- Form 4 TScan Therapeutics, Inc. For: May 20 Filed by: Gruia Gabriela
Entities mentioned with TCRX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Morgan Stanley | View Related Stories »
- S3 | View Related Stories »
- Cowen & Co | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
